Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, December 15, 2015

Neuroscientists: Shroom-induced brain rewiring could hold the key to fighting mental illness - psilocybin

The picture from there showing the enhanced brain connections is great.  This joins marijuana, ecstasy and levodopa as possible help in stroke recovery. But this will never occur with our fossilized Congress.
Neuroscientists: Shroom-induced brain rewiring could hold the key to fighting mental illness
Psychedelic mushrooms dramatically increase connectivity between otherwise uncommunicative parts of the brain, according to researchers from Imperial College London in an article to be published in the November edition of the Royal Society’s journal Interface.
Paul Expert and his team analyzed functional magnetic resonance imaging (fMRI) data from two groups of people — one who had ingested a small amount of the active agent in hallucinogenic mushrooms, psilocybin, and another group who was given a placebo.
On the left is a data visualization of a brain administered the placebo; on the right, one that has been subjected to a mild dose of psilocybin.

No comments:

Post a Comment